At Moffitt Cancer Center, we take an individualized approach to HER2 positive breast cancer treatment. The experts in our Don & Erika Wallace Comprehensive Breast Program focus exclusively on breast malignancies, and collaborate to ensure each patient receives a treatment plan that has been tailored to address their unique needs. Our individualized treatment plans, in combination with our physicians’ outstanding expertise, consistently leads to the best possible outcomes and improved quality of life for our patients.
HER2-targeted therapies
HER2 positive breast cancer requires a different treatment approach than other kinds of breast cancer. This malignancy typically responds best to therapies that are specifically for HER2 positive breast cancer. Some of these treatments include:
- Trastuzumab (Herceptin), Neratinib (Nerlynx) and Pertuzumab (Perjeta) – Blocks the cancer cells’ ability to receive growth signals
- Lapatinib (Tykerb) – Blocks certain proteins that can lead to uncontrolled cell growth
- Ado-trastuzumab emtansine (Kadcyla) – Delivers chemotherapy to the HER2 positive cancer cells by attaching emtansine to Herceptin.
Other treatments for HER2 positive breast cancer
In addition to HER2-targeted therapies, there are also several standard chemotherapy drugs that are used to treat HER2 positive breast cancer. While these medications do not target the HER2 protein specifically, many patients have experienced positive results through the use of these medications.
Additionally, treatment for HER2 positive breast cancer is advancing every day. Several new medications that also target the HER2 protein are being tested in clinical trials. Moffitt has been designated as a Comprehensive Cancer Center by the National Cancer Institute, an achievement that speaks directly to our dedication to advancing cancer research and treatment. Through our robust clinical trials program, eligible patients have the opportunity to benefit from the latest breakthroughs in treatment before they are made available elsewhere.
To speak with a Moffitt physician about your HER2 positive breast cancer treatment options, request a consultation by completing a new patient registration form online or calling 1-888-663-3488. We do not require referrals.
